AU617526B2 - A novel immunodiagnostic method - Google Patents
A novel immunodiagnostic method Download PDFInfo
- Publication number
- AU617526B2 AU617526B2 AU41429/89A AU4142989A AU617526B2 AU 617526 B2 AU617526 B2 AU 617526B2 AU 41429/89 A AU41429/89 A AU 41429/89A AU 4142989 A AU4142989 A AU 4142989A AU 617526 B2 AU617526 B2 AU 617526B2
- Authority
- AU
- Australia
- Prior art keywords
- antigens
- antigen
- apparent molecular
- sds
- cysticercus cellulosae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 18
- 102000036639 antigens Human genes 0.000 claims description 83
- 108091007433 antigens Proteins 0.000 claims description 83
- 239000000427 antigen Substances 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 201000000077 Cysticercosis Diseases 0.000 claims description 27
- 239000002609 medium Substances 0.000 claims description 20
- 241000244157 Taenia solium Species 0.000 claims description 19
- 208000007316 Neurocysticercosis Diseases 0.000 claims description 17
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 206010061217 Infestation Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 235000015277 pork Nutrition 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000031513 cyst Diseases 0.000 description 37
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 28
- 206010011732 Cyst Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 12
- 208000004441 taeniasis Diseases 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 10
- 206010027259 Meningitis tuberculous Diseases 0.000 description 9
- 208000022971 Tuberculous meningitis Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 208000001223 meningeal tuberculosis Diseases 0.000 description 9
- 244000045947 parasite Species 0.000 description 9
- 229960004452 methionine Drugs 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 201000009906 Meningitis Diseases 0.000 description 6
- 241000942597 Scolex Species 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 244000000013 helminth Species 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003071 parasitic effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000009950 chronic meningitis Diseases 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001418 larval effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 101000746317 Bos taurus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FJKFBLLIOVQLFS-UHFFFAOYSA-L dibenzoyloxymercury Chemical compound [Hg+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 FJKFBLLIOVQLFS-UHFFFAOYSA-L 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4355—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from cestodes
- C07K14/43554—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from cestodes from Taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Description
COMMONWEALTH OF AUSTRAL 1 7 2 6 PATENTS ACT 1952 FORM Class: Int. Class Application Number: Lodged: Complete specification: Lodged: Accepted: Published: Priority: Related Art: a Name of Applicant: AKTIEBOLAGET ASTRA Address of Applicant: S-151 85 Sodertalje, Sweden.
Actual Inventor/s: BV RAVI KUMAR; V SURYANARAYANA; V RAVI; and A CHANDRAMUKHI.
Address for Service: E.F. WELLINGTON CO., Patent and Trade Mark Attorneys, 457 St. Kilda Road, Melbourne, 3004, Victoria.
Complete Specification for the invention entitled: "A NOVEL IMMUNODIAGNOSTIC METHOD" The following statement is a full description of this invention including the best method of performing it known to us.
uOczae4 c~a~~a 1 -I i i Background of the invention Field of Invention: Cysticercus cellulosae, the larval form of the tapeworm Taenia solium can infest human brain leading to serious neurological syndromes collectively described as Neurocysticercosis (NCC). Depending on the intra cranial location of the cyst the following clinical presentations are often seen.
Location Clinical syndrome Sequelae Brain Parenchyma Epilepsy Space occupying lesion (SOL) Psychosis Encephalitis Chronic Meningitis Motor or Sensory deficit Meninges Hydrocephalus Cranial nerve palsies Motor Sensory deficit SOL Hydrocephalus Ventricles All the clinical syndromes described here can be caused by many aetiological factors, the commonest differential diagnosis for neurocysticercosis being the Mycobacterium tuberculosis infections of the nervous system.
Diagnosis of this disease is made based on radiological examination of the skull. Dead calcified cysts appear I as dense radioopaque lesions on the X-ray of the skull, while the live cysts appear as hypodense or hyperdense lesions on computerised tomography (CAT-SCAN). Recently magnetic resonance imaging (MRI) of central nervous system (CNS) is applied to visualise the live cysts.
Identification of a cyst in any of these imaging procedures largely depends on the size of the cyst and the reaction of the surrounding host tissue. In many developing countries where the disease is prevalent imaging facilities are not easily accessible creating an acute necessity for an alternative simpler method for the diagnosis. Thus, there is a need for an immunodiagnostic test that can discriminate neurocysticercosis from Sother neurological illnesses. Majority of the existing immunological tests aim at detection of antibodies against the antigens of the organism being identified.
Moreover, many tests were developed as sero diagnostic tests to be used in epidemiological surveys and these 0 o° existing tests were not designed for a very specific diagnosis of neurocysticercosis.
The specificity and sensitivity of the test largely depends on the antigen which is used in the test. The present invention describes a method of preparation of antigens of Cysticercus cellulosae that can confer specificity and sensitivity to immunodiagnosis.
3 ~PI Prior art in the antigen preparation and immunodiagnosis: Crude extracts of the larvae of T.solium were prepared as total homogenates of the cyst, or homogenates of the solid parts of the cysts i.e. bladder wall and the scolex or the bladder wall alone In certain cases vesicular fluid was also used as an antigen The homogenates were usually subjected to a centrifugation to remove cell debris, nuclei etc at 15000-20000 x g for 15 to 30 minutes. The total homogenate was extracted with acetone to remove majority of lipids and was used in complement fixation test The crude or total o antigens were used in many type. of immunoassays like passive haemagglutination test (5 3) immunoelectrophoresis and enzyme linked immunosorbent assay [(ELISA) (1,6 and oo. Using a total homogenate of the cyst, Kuhn et.al. (8) 0 o0 described an ELISA and attributed the sensitivity of the test to a set of antigens among the proteins. These antigens were neither purified nor tested for their specificity. The total homogenate contains antigenic lipids and carbohydrates in addition to the proteins visualised and identified as immunogenic on western blotting. The contribution of the non protein antigens to the total sensitivity of the ELISA was not verified.
A single antigen identified as antigen B exhibiting the properties of fibronectin was used in ELISA but the rr sensiti 7ity was not satisfactory 1 i Total homogenate of the parasite presents several disadvantages as antigen in immunodiagnosis. It contains several epitopes having immunological cross reactivity with other CNS pathogens (vide infra) (ii) It has been shown that several parasitic helminths share cross reactive antigens In developing countries such as India, Mexico, Brazil, China, Thailand and countries in Central America and Asia where parasitic infestation among the population often is very common, a considerable number of people harbour serum antibodies to the cross reactive antigens. When such individuals are affected by diseases which breach the blood brain barrier, the serum antibodies can enter cerebrospinal fluid (CSF) and interfere with diagnosis of cysticercosis giving false positive results.
In view of the lack of specificity of total homogenates attempts were made to identify and purify species and tissue specific antigens viz., antigens derived from scolex and vesicular fluid. Two polypeptides of apparent mol wts of about 26,000 and about 8,000 were identified as species specific antigens of Taenia solium. These antigens reacted in an immunoblot with serum obtained from patients with Taenia solium infection and not with sera of patients with other helminthic infestations The sensitivity of these antigens t s ILI~_ or specificity with respect to other related CNS disorders is not yet verified. An antigen purified from vesicular fluid using a monoclonal antibody raised against total proteins of the vesicular fluid proved very specific in immunodiagnosis but lacked the required sensitivity to be useful in detection of NCC (12).
Scolex specific proteins of apparent mol wts of about 80,000 and about 10,000 purified using monoclonal antibodies conferred 1009 sensitivity to serodiagnosis of cysticercosis. It was claimed that these antigens were useful to discriminate between taeniasis and cysticercosis. Its usefulness in discriminating neurocysticercosis from other systemic cysticercosis was not tested (13).
The disadvantage of using the total homogenate as antigen could be further illustrated by a study conducted at the laboratory of the inventors This study is summarised below: Cysts were homogenised and sonicated (3x30 second pulses). Homogenates solubilised in 1% SDS and treated with 1% B mercaptoethanol at 100 C were subjected to gel filtration on Sephacryl S-300 column to be resolved into three fractions:
I--
i/ i n i
I
ii I i i ii Fraction I cyst antigens of mol.wt 66 K Daltons Fraction II cyst antigens of mol.wt between 25 K-66 K Daltons Fraction III: cyst antigens of mol.wt between 14 K-35 K Daltons (Fig 1) Legend for Fig.l:Three peak fractions obtained on gel filtration were analysed on 10% SDS-PAGE. Lane 1:3rd peak Lane 2:2nd peak, Lane 3: 1st peak. Lane 4:Mr markers(94,67,43,30,20.1 14.1 KDa). The Mr ranges of the three fractions are given in the text.
4 4: 0 o 0 001 o 0 ELISA, using the above three fraction of cysticercal antigens was performed in the following way: 150 CSFs collected randomly from various neurological patients were tested against these three fractions. Antigens were coated on 96 well microtitre plates of Dynatech at 0; 0 i concentrations of 5 ug/ml (100 pl/well) in 50 mM bicarbonate buffer pH 9.6 overnight, quenched with 2% BSA and CSFs were tested at 1/25, 1/125 and 1/625 dilutions. Bound human IgG was revealed using rabbit anti-human IgG peroxidase conjugate (Sigma,1:1000 dilution). Orthophenylene diamine was used as chromogen 4 mg/10 ml) and 0.34 H 0 as substrate.
Table 1 summarises the results of these 150 samples.
7 TABLE 1 Fraction Fraction Fraction Si Diagnosis3 No of No. cases 4+4- 1 Cysticercosis CAT-SCAN proven 6 6 4 2 2 2 2 2 Tuberculous Meningitis (TBM) culture proven 11 5 4 1 4 3 4 1 2 3 TBM strongly suspected 24 3 5 4 4 1 5 3 2 3 4 Chronic Meningitis aetiology untraceable 20 5 4 4 5 6 Pyogenic meningitis culture proven 7 6 Multiple Sclerosia swedisda samples 30 7 Brain tumours Dernentias Epilepsy Viral Encephalitis 52- CSFs 4-ye upto a dilution of 1/625; CSFs 4-va upto a dilution of 1/125 only; CSFs 4-ye upto a dilution of .1/25 only. Average absorbency at 490 nin of categories 2,3 and 4 are 3-5 times less than category 1.
I
Following conclusions were drawn from this data.
Though the test was sensitive enough to recognise all cases of neurocysticercosis, the maximum false positive results were given by the cases of tuberculous meningitis. Therefore, the test is not useful wherever both diseases are prevalent.
Reaction of tuberculous meningitis CSFs with cyst antigens was shown to be due to cross-reactvity between mycobacterial antigens and the cyst antigens.
1. Mycobacterium tuberculosis sonicates inhibited the binding of cysticercosis positive CSFs to cyst anitgens but did not totally abolish the reaction.
2. This inhibition increased with increasing concentrations of mycobacterial antigens.
3.Rabbit antiserum raised against mycobacterial sonicates reacted with cyst antigens.
The above observations illustrated that crude antigens indeed contained epitopes that cross reacted with other CNS pathogens.
Cysticerci are multicellular organisms that cannot be phagocytised and processed by macrophages or granulocytes or other antigen presenting cells unlike the unicellular microorganisms. Therefore, the human immune system rarely gets sensitised to all the proteins of the parasites, the more so in an immunologically priveliged compartment like CNS. So, the antigens that are secreted or excreted or shed by these parasites into body fluids of the host (termed as E-S antigens) are immunologically very important. E-S antigens of many parasitic helminths were obtained by maintaining various developmen tal stages of the helminths in vitro in tissue culture media and purifying the antigens from the growth media Cysticercus cellulosae were also maintained in vitro with serum and tissue extracts On keeping these parasites for short periods of time in Dulbecco's minimal essential medium (DMEM) or phosphate bufferec S13 saline (PBS) and pulsing these parasites with C amino Sacids, it was shown that they were metabolically active However, only negligible amounts of radioactively labelled proteins were detected in the medium. The utility of these antigens in immunodiagnosis was never tested.
Details of the disclosure or invention: The present invention is based on the premise that E-S antigens of cysticercus cellulosae obtained by maintaining the parasites in vitro may be closely related to the antigens that come out of cyst as a part of cyst metabolic processes in vivo. Thus they may confer Jspecificity and sensitivity to the immunodiagnostic tests designed to detect antibodies in the body fluids of the patients such as CSF and serum. Same antigens or some degraded products of these antigens may be found in CSFs of the patients. This would form the basis for designing immunodiagnostics based on antigen detection.
It is understood that it is possible to develop pclyi i i I clonal monoSpecific or monoclonal antibodies against the E-S antigens which then could be used in such an antigen detection test. As some of these antigens may confer protective immunity to the host these antigens may be used for developing vaccines to neutralize the infestations by cysticercus cellulosae.
By the present invention we describe a novel method of maintaining cysticercus cellulosae in serum free cell culture media for extended periods of time and using the antigens elaborated by the parasite into the medium for immunodiagnosis of NCC involving interaction of CSF of the patients with the E-S antigens. The emphasis here is the use of the antigens in identifying NCC without any interference by other forms of systemic cysticercosis.
The novel method of diagnosis described may also be useful in diagnosing cysticercus cellulcsae infestation of pigs intended for human consumption.
Source and maintenance of cysts: Pork muscle infested with cysticerci are obtained from abattior. Pork muscle is wiped clean off contaminants on the surface with ethanol. Cysts are dissected out intact without rupturing the bladder wall (if ruptured the cyst is discarded) and placed in saline containing Pencillin G 1000 units/ml, Gentamycin 40 ugs/ml and Amphotericin B 5 ugs/ml. Cysts are thoroughly washed with sterile saline containing antibiotics as above. They are then i washed with serum free medium RPMI 1640 or Eagles minimal essential medium (MEM) with Earles salts or Hank's salts. Cysts are placed in RPMI 1640 or Eagles MEM containing Pencillin G 1000 units/ml and Gentamycin 40pg/ml at 37 C with 5% COt.
Collection of E-S antigen: The medium is changed and discarded atleast twice during the first 24-60 hours to ensure complete removal of host components. Suitably,the medium can be replaced twice during the first 48 hours. The medium is collected I 'at intervals from then on until cysts start evaginating.
Suitably, for practical reasons, the medium is collected every 24 hours. Viability of the cysts is monitered by bladder wall contractions that can be observed under an inverted microscope. Evagination is observed from the 6th day onwards. Soon after collection of the medium it is centrifuged at 104,000 x g for 60 min. to remove any insoluble debris and membrane contamiiiants. To the supernatant are added paramethyl sulphonyl fluoride (2 mM parachloro mercury benzoate and ammonium sulphate to a saturation of 90% maintaining the pH of the solution at 7-7.4. The precipitation is carried out at 4 C and subsequently collected by centrifugation at 15,000xg for 30 mins at 4 C. The precipitate is dissolved in 50 mM sodium phosphate buffer pH 7.4 and extensively dialysed against the same buffer with several changes for 48 hours. Alternatively the membrane fragments can be removed by other methods known in the art such as membrane filtration. Similarly antigens can be isolated by other methods such as ultrafiltration. UV spectrum of the solution shows an absorption maximum at 278-280 nm. Protein estimated by Schaffner and Weissmann (18) procedure gives 25-35 pg protein/cyst/24 hrs,when cysts are maintained at a parasite density of cysts 10 ml.
Sodium Dodecyl Sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of these proteins stained with coomassie blue R is given in Fig 2.
Legend for Fig.2: Coomassie blue staining of E-S proteins analysed on 7.5 -15% gradient SDS-PAGE .Lane l:High Mr markers (116,97.4,66,45 and 29 KDa) Lanes 2 3 Ammonium sulphate precipitated E-S proteins of two independent preparations, Lane 4: Low Mr markers (94,67,43,30,20.1 and 14.4 KDa) Major protein bands seen are of apparent molecular weight of about 97000, 66000, 50000, 38000, 28000 and an unresolved mixture of proteins of apparent molecular weights in the range of 10000-14000 daltons. A number of minor bands are also seen.
Evidence for de novo synthesis of E-S proteins:.
Cysts after the first 48 hours in the medium, were transferred to methionine deficient medium containing methionine 40 p Ci/cyst. The cysts and the medium were taken at various time points. The cysts were dissected out into bladder wall and scolex and homogenised. The homogenates were analysed on 12% SDS-PAGE and sujbected to flourography. The medium was acetone precipitated and analysed on 12% SDS-PAGE and subjected to flourography.
There was an active incorporation of aS-methionine both into bladder wall and scolex proteins.
By 48 hrs several proteins appeared in the medium (Fig.3) Legend for Fig.3: Autoradiogram of Excretory/Secretory proteins labelled with S-methionine 3 cysts were incubated separately in 1 ml of medium each containing 40 uci of 3 S- methionine for 48 hrs. Medium was collected,subjected to ultracentrifugation and the supernatant was acetone precipitated. Each lane represents protein from a single cyst.
As is seen in Fig.3 several proteins were actively synthesised excreted/secreted into the medium as a part of the metabolic activity of the parasite.
Summary of the Invention: When cysts are maintained in vitro in serum free media, as a part of metabolic turnover, some protein antigens appear in the medium either by a process of excretion or secretion. These antigens collected before the evagination of scolex represent antigens of larval stages. The antigens, the method for their preparation and their use for diagnosis and possibly prognosis of 14 NCC is claimed as well as their intended use in production of vaccine against the infestation of cysticercus cellulosae. The diagnostic method described here may also be used to diagnose cysticercosis in pigs intended for human consumption.
Such modified form could for example be polyethylene glycol linking or cross-linking with other proteins or bifunctional reagents or digesting with proteases. The invention also relates to a method of diagnosing active o, 10 human NCC which comprises interacting CSF from a human o to be diagnosed with at least one excreted or secreted antigen of in vitro maintained cysticercus cellulosae o 0 having an apparent molecular weight as determined by a SDS-PAGE of about 97,000 or 66,000 or 50,000 or 38,000 daltons or a mixture of said antigens.
Examples: S Example 1 and 2 relate to the utility of these antigens Sin an ELISA system to detect anti cysticercal antibodies o in CSF of patients with various neurological disorders.
Examples 3 and 4 relate to further identification of important antigens by their molecular weight in immunon precipitation using patients CSF.
EXAMPLE 1: Secretory/Excretory proteins collected as described in the disclosure are coated on rigid 96 well microtitre plates of Dynatech at a concentration of 5 pg protein/ml (100 pl/well) overnight at room temperature. The remair ning protein binding sites of the plates were quenched using 2% bovine serum albumin (BSA) in PBS. CSFs diluted 1/25, 1/125 and 1/625 in phosphate buffered saline containing 0.05% tween-20 (PBST) and incubated for 2 hrs at 37 C. After the incubation, wells were washed thrice with PBST. Rabbit anti human IgG peroxidase conjugate diluted 1:1000 in PBST was used in a volume of 100 pl/well o and incubated for 2 hrs at 37 C after which the wells were washed thrice with PBST. Bound conjugate was re- 10 vealed in 20 mins using orthophenylene diamine as o chromogen (4 mg/10 ml) and H 0 as substrate. The reaction was stopped with 50 pl of 4N H SO and absorbency at 490 S nm was determined in Dynatech MR 700 ELISA reader. Any absorbency value greater than 0.10 at a CSF dilution of 1/100 was considered positive.
Table 2 contains the results.
cQc o C o 0 O oC 0 o
O
O O O O Diagnosis No of Positives samples Cysticercosis Postmortem proven Surgery proven Clinically suspected Japanese Encephalitis IgM capture ELISA +ve Tuberculous meningitis Culture proven surgery proven Tuberculous meningitis (either Ag+ve or antibody +ve) 2 absorbency =0.15 490nm The above table shows that this antigen is superior to the crude antigen and confers specificity to immunological reaction.
EXAMPLE 2 This example describes a double blind study of the diagnostic value of excretory-secretory antigens in which the design of the test eliminates the bias of the investigator performing the test.
37 CSF samples obtained from patients with various neurological disorders with confirmed diagnosis were given serial numbers from 1 to 37 by an unbiased observer other than the inventors. The samples were aliquoted into three sets. Two independent laboratories of the inventors received the CSF samples and two persons in each laboratory i.e. a total of 4 persons conducted the ELISA independently as described in detail in example 1. All four investigators tabulated the results and communicated the results to the unbiased observer. The results of all four investigators were identical and are given in table 3.
17 blotting. The contribution of the non protein antigens to the total sensitivity of the ELISA was not verified.
A single antigen identified as antigen B exhibiting the properties of fibronectin was used in ELISA but the 4 FLI_,.JI~ k- TABLE 3 n
~I
u, DIAGNOSIS NO OF POSITIVES Neurocysticercosis 3 3 Spinal anaesthesia (Normal controls) 8 0 Post Operative meningitis (culture proven) 5 0 Japanese Encephalitis 7 0 Pyogenic Meningitis (Pneumococcal) 3 0 0 0 Cryptococcal Meningitis (Culture proven) 1 0 Tuberculous Meningitis (Culture proven) 2 0 Thoracic cord compression 2 0 Cranio Vertebral Junction Anomaly 1 0 S Prolapsed Intervertebral disc 1 0 Motor neurcon disease 1 0 Ataxic neuropathy 1 0 Hemiplegia 1 0 Pseudobulbar palsy 1 0 The above results indicate that excretory-secretory antigens can confer 100% sensitivity and 100% specificity to a diagnostic test designed to detect antibodies in CSFs of patients.
0 I_ L EXAMPLE 3 Secretory/excretory antigens obtained as described in the invention were labelled with152s using the lodogen method. The labelled proteins were incubated with CSFs from known neurocysticercosis, tuberculous meningitis and various other neurological disorders. Immune complexes were brought down with rabbit anti human IgG, carrier human IgG and making the whole solution to 1 polyethylene glycol. The precipitates were analysed on a gradient SDS-PAGE of 15% which was subjected to S autoradiography Fig.4.
Legend for Fig.4. Autoradiogram of I labelled secretory/excretory proteins immunoprecipitates with CSFs of a 15 patients. CSF (30 ul) in 1: 3 dilutions was incubated with E-S proteins (3x10 cpm) and immune complexes were precipitated as stated in the text. Lane 1. Control-No CSF.;Lanes 2,3&4 CSF from neurocysticercosis, Lane berculous meningitis, Lanes 6,7 8 other neurological disorders.
Significantly, proteins of apparent molecular weight of about 97 kDa, 66 kDa, 50 kDa and 38 kDa were brought down in immunoprecipitation.
EXAMPLE 4: 3C E-S proteins labelled with S methionine by maintaining 19 r, r-- 1~11~141..1~1~11111~ I)i the cysts in vitro in methionine deficient medium containing S-methionine were immmunoprecipitated with CSF antibodies as mentioned in example 2. The flourography of SDS-PAGE of the immunoprecipitates is shown in Legend for fig 5: Autoradiogram of S labelled E-S protein immunoprecipitated with CSFs of patients with various neurological disorders. Lanes 9 and 5 represent immunoprecipitates from CSFs of NCC patients.
As in Example 3, 97, 66, and 50 kDa proteins are immunoprecipitated here also.
References cited: 1. Espinoza, B. et.al (1982) in A.Flisser et al (ed) Cysticercosis Present state of knowledge and perspectives 163-170 Academic Press,New York.
2. Rosas, N. et.al. (1986) Arch. Neurol., 43, 353-356.
3. Larralde, C.et.al. (1986) in Am.J.Trop.Med.Hyg., 965-974.
4. Neito, (1956) Neurology 6, 725-738.
5. Powell, S.J. et.al. (1966), Ann.Trop. Med. Parasitol 152-158.
6. Diwan, A.R.et.al. (1982) Amr.J.Tro.Med.Hyg. 31 364- 369.
7. Estrada, and Kuhn, (1985) J.of Neurol.
Sciences 71 39-48.
8. Kuhn, R.E. et.al. US Paten,: No. 4,740,456. (1988).
9. Espinoza, B.et.al. (1986), J.Clin.Microbiol. 24, 536-541 Espinoza, B. and Flisser, A, (198"1) Arch..Inves tigative Medicine 17 299-312.
11 Gottestein. 3. e t i. ~1937 Tro Med -P ars it 3 3 299- 303.
12. K im,S.T.et.al. t1l936) Korean J.Parasir-l. 14 145-158.
13. Nlascinento,E. et.aI.(1387)J.of Cli.icrobiol.25 1181 -1185.
1,01 14. Suryanarayana,V.et.al. (1987) Abstract No. SVIIA-5, 37th Annual Conference of the Neurological Society of India, .1 Hyderabad LightwersM.W.,and Rickard, Parasitology (1988), 96, S123-S166.
16. J.Sotelo et al, J.Amn.Med.Assoc. (1986), 256.893.
17. Diaz De Leon, L.et.al. (1982) in A.Flisser et al (ed) Cysticercosis Present State of knowledge and perspec- V tives, 465-475, Academic Press, New York.
18. Schaffner, W.and Weisszmann, (1973) Anal.Biochem.
56 502-514.
The matter contained in each of the following claim is to be read as part of the creneral description of the present invention.
Claims (11)
1. The use of excretory/secretory antigens of cysticercus cellulosae in immunodiagnosis of neurocysticercosis.
2. The use according to claim 1 in which antigens of apparent molecular weights of about 97,000, 66,000, 50,000 and 38,000 are utilised.
3. The use according to claim 1 wherein the antigens of apparent molecular weights of 66,000 and 38,000 are utilised.
4. The use according to any one of claims 1,2 and 3 wherein the immunoassay is designed to detect antibodies in body fluids of patients such as CSF and serum. The use according to any one of claims 1,2 and 3 wherein the immunoassay is designed to detect antigen in the body fluids of patients such as CSF and serum. The procedure using in vitro maintenance of cysticercus cellulosae for the preparation of antigens as defined in claim 2 or 3.
7. An antigen excreted/secreted by cysticercus cellulosae which has an apparent molecular weight of about 97,000 or 66,000 or 50,000 or 38,000 daltons as estimated by SDS-PAGE.
8. An antigen according to claim 7 characterised in that it is a glycoprotein of apparent molecular weight of about 97,000 or 50,000 as estimated by SDS-PAGE.
9. An antigen according to claim 7 wherein the protein i of apparent molecular weight of about 38,000 comprises a partial amino acid sequence valine-glutamic acid- tyrosine-threonine-cysteine-threonine (VEYTCT). An antigen obtainable by secretion or excretion by cysticercus cellulosae which has an apparent molecular weight of about 97,000 or 66,000 or 50,000 or 38,000 as estimated by SDS-PAGE.
11. An antigen obtainable by secretion or excretion by cysticercus cellulosae which is a glycoprotein of apparent moleculkr weight of about 97,000 or about 50,000 as estimated by SDS-PAGE.
12. An antigen obtainable by secretion or excretion by cysticercus cellulosae comprising a partial amino acid sequence of valine-glutamic acid-tyrosine-threonine- cysteine-threonine, (VEYTCT)
13. The use of an antigen according to any one of claims 7,8,9,10,11 and 12 in the preparation of vaccine against infestation of cysticercus cellulosae.
14. A process for obtaining an antigen as defined in claim 7,8 or 9 comprising the following steps maintaining intact and undamaged cysticerci from infested pork muscle in vitro in serum free cell culture growth medium containing antibiotics, removing all the antigens in the first 24-60 hours of the maintenance by repeatedly replacing the medium, subsequently collecting the medium at intervals until the time of evagination, (d)removing any membrane Iragments, and isolation of the antigens. A method for diagnosing active human NCC which comprises: interacting CSF from a human to be diagnosed with at least one excreted or secreted antigen of in vitro o 5 cultured cysticercus cellulosae having an apparent molecular weight as determined by SDS-PAGE of about 97,000 or 66,000 or 50,000 or 38,000 daltons or a mixture of said antigens. DATED this 15th day of September, A.D.1989 AKTIEBOLAGET ASTRA, By its Patent Attorneys, E. F. WELLINGTON CO., By: BRUCE S. WELLINGTON
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN655MA1988 IN172551B (en) | 1988-09-19 | 1988-09-19 | |
IN655/88 | 1988-09-19 | ||
SE19898900243A SE8900243D0 (en) | 1989-01-24 | 1989-01-24 | A NOVEL IMMUNODIAGNOSTIC METHOD |
SE8900243 | 1989-01-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4142989A AU4142989A (en) | 1990-03-22 |
AU617526B2 true AU617526B2 (en) | 1991-11-28 |
Family
ID=26324816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU41429/89A Expired AU617526B2 (en) | 1988-09-19 | 1989-09-15 | A novel immunodiagnostic method |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU617526B2 (en) |
CA (1) | CA1340196C (en) |
GB (1) | GB2223757B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4740456A (en) * | 1985-08-15 | 1988-04-26 | Wake Forest University | Immunological methods for diagnosing neurocysticercosis |
-
1989
- 1989-09-15 AU AU41429/89A patent/AU617526B2/en not_active Expired
- 1989-09-15 GB GB8920931A patent/GB2223757B/en not_active Expired - Lifetime
- 1989-09-18 CA CA000611731A patent/CA1340196C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GB8920931D0 (en) | 1989-11-01 |
GB2223757A (en) | 1990-04-18 |
CA1340196C (en) | 1998-12-15 |
AU4142989A (en) | 1990-03-22 |
GB2223757B (en) | 1992-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ryder et al. | Enterotoxigenic Escherichia coli and reovirus-like agent in rural Bangladesh | |
Blaser et al. | Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children | |
Winslow et al. | Evaluation of a commercial enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody in diagnosis of human leptospiral infection | |
Coleman et al. | Comparative evaluation of selected diagnostic assays for the detection of IgG and IgM antibody to Orientia tsutsugamushi in Thailand. | |
EP2322932B1 (en) | Detection of tuberculosis and infection by mycobacterium tuberculosis using HBHA | |
Casemore | The antibody response to Cryptosporidium: development of a serological test and its use in a study of immunologically normal persons | |
Dharmkrong-At et al. | Enzyme-linked immunosorbent assay for detection of antibody to Gnathostoma antigen in patients with intermittent cutaneous migratory swelling | |
Philip et al. | Fluorescent antibody responses to chlamydial infection in patients with lymphogranuloma venereum and urethritis | |
Coker-Vann et al. | Serodiagnosis of human cysticercosis using a chromatofocused antigenic preparation of Taenia solium cysticerci in an enzyme-linked immunosorbent assay (ELISA) | |
Quilez et al. | Comparison of an acid-fast stain and a monoclonal antibody-based immunofluorescence reagent for the detection of Cryptosporidium oocysts in faecal specimens from cattle and pigs | |
Molinari et al. | Discrimination between active and inactive neurocysticercosis by metacestode excretory/secretory antigens of Taenia solium in an enzyme-linked immunosorbent assay. | |
Lesourd et al. | Specific immune responses to skin test antigens following repeated multiple antigen skin tests in normal individuals | |
EP0456686B1 (en) | Excretory/secretory antigens of tapeworm (cysticercus cellulosae) for use in immunodiagnosis and vaccine preparation | |
AU617526B2 (en) | A novel immunodiagnostic method | |
Chan et al. | Prevalence of Dientamoeba fragilis antibodies in children and recognition of a 39 kDa immunodominant protein antigen of the organism | |
US4740456A (en) | Immunological methods for diagnosing neurocysticercosis | |
Akao et al. | A rapid and sensitive screening kit for the detection of anti-Toxocara larval ES antibodies | |
Kagan et al. | Studies on echinococcosis: nonspecific serologic reactions of hydatid-fluid antigen with serum of patients ill with diseases other than echinococcosis | |
Pammenter et al. | The value of an antigenic fraction of Cysticercus cellulosae in the serodiagnosis of cysticercosis | |
Hechemy et al. | Immunoblot studies to analyze antibody to the Rickettsia typhi group antigen in sera from patients with acute febrile cerebrovasculitis | |
Reimann et al. | AN INDIRECT HAEMAGGLUTINATION TEST FOR DEMONSTRATION OF GONOCOCCAL ANTIBODIES USING GONOCOCCAL PILI AS ANTIGEN: II. Serological Investigation of Patients Attending a Dermato‐venereological Outpatients Clinic in Copenhagen | |
Hashkes et al. | Salivary IgA antibodies to Giardia lamblia in day care center children | |
Jackson et al. | Plate hemolysin test for the rapid screening of toxoplasma antibodies | |
US4855408A (en) | Antigens for diagnosing neurocysticercosis | |
Purwaningsih et al. | Diagnostic value of dot-enzyme-immunoassay test to detect outer membrane protein antigen in sera of patients with typhoid fever |